Chronic alloantibody mediated rejection

Seminars in Immunology

Volumn 24, Issue 2, 2012, Pages 115-121

  Smith, R Neal ^a   Colvin, Robert B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alloantibodies; Antibody mediated rejections; Chronic rejection; Complement; Human allografts

Indexed keywords

ALLOANTIBODY; BORTEZOMIB; CALCINEURIN INHIBITOR; COMPLEMENT; COMPLEMENT COMPONENT C4D; FC RECEPTOR; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; CHRONIC ALLOANTIBODY MEDIATED REJECTION; COMPLEMENT ACTIVATION; DISEASE COURSE; DRUG EFFICACY; EFFECTOR CELL; GENE ACTIVATION; GLOMERULOPATHY; GRAFT REJECTION; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PLASMA CELL; PREVALENCE; PROTEINURIA; REVIEW; RISK FACTOR; TREATMENT INDICATION;

CHRONIC DISEASE; COMPLEMENT SYSTEM PROTEINS; GRAFT REJECTION; HUMANS; ISOANTIBODIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84859268856     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2011.09.002     Document Type: Review

References (125)

1. Jeannet M., Pinn V.W., Flax M.H., Winn H.J., Russell P.S. Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970, 282:111-117.
2. Terasaki P.I., Ozawa M., Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007, 7:408-415.
3. Worthington J.E., Martin S., Al-Husseini D.M., Dyer P.A., Johnson R.W. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003, 75:1034-1040.
4. Opelz G., Dohler B., Susal C. Analysis of positive kidney, heart, and liver transplant crossmatches reported to the Collaborative Transplant Study. Hum Immunol 2009, 70:627-630.
5. Halloran P.F., Wadgymar A., Ritchie S., Falk J., Solez K., Srinivasa N.S. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 1990, 49:85-91.
6. Trpkov K., Campbell P., Pazderka F., Cockfield S., Solez K., Halloran P.F. Pathologic features of acute renal allograft rejection associated with donor-specific antibody analysis using the Banff grading schema. Transplantation 1996, 61:1586-1592.
7. Feucht H.E., Felber E., Gokel M.J., Hillebrand G., Nattermann U., Brockmeyer C., et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991, 86:464-470.
8. Collins A.B., Schneeberger E.E., Pascual M.A., Saidman S.L., Williams W.W., Tolkoff-Rubin N., et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999, 10:2208-2214.
9. Mauiyyedi S., Colvin R.B. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002, 11:609-618.
10. Racusen L.C., Colvin R.B., Solez K., Mihatsch M.J., Halloran P.F., Campbell P.M., et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003, 3:708-714.
11. Mauiyyedi S., Pelle P.D., Saidman S., Collins A.B., Pascual M., Tolkoff-Rubin N.E., et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001, 12:574-582.
12. Takemoto S.K., Zeevi A., Feng S., Colvin R.B., Jordan S., Kobashigawa J., et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004, 4:1033-1041.
13. Regele H., Bohmig G.A., Habicht A., Gollowitzer D., Schillinger M., Rockenschaub S., et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002, 13:2371-2380.
14. Haas M., Rahman M.H., Racusen L.C., Kraus E.S., Bagnasco S.M., Segev D.L., et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 2006, 6:1829-1840.
15. Scornik J.C., Guerra G., Schold J.D., Srinivas T.R., Dragun D., Meier-Kriesche H.U. Value of posttransplant antibody tests in the evaluation of patients with renal graft dysfunction. Am J Transplant 2007, 7:1808-1814.
16. Sis B., Campbell P.M., Mueller T., Hunter C., Cockfield S.M., Cruz J., et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007, 7:1743-1752.
17. Bohmig G.A., Exner M., Habicht A., Schillinger M., Lang U., Kletzmayr J., et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002, 13:1091-1099.
18. Kraus E.S., Parekh R.S., Oberai P., Lepley D., Segev D.L., Bagnasco S., et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009, 9:1826-1834.
19. Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005, 365:1570-1576.
20. Piazza A., Poggi E., Borrelli L., Servetti S., Monaco P.I., Buonomo O., et al. Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: posttransplant analysis using flow cytometric techniques. Transplantation 2001, 71:1106-1112.
21. Suciu-Foca N., Reed E., D'Agati V.D., Ho E., Cohen D.J., Benvenisty A.I., et al. Antigens, anti-HLA antibodies, and antiidiotypic antibodies in the circulation of renal transplant recipients. Transplantation 1991, 51:593-601.
22. Terasaki PI Humoral theory of transplantation. Am J Transplant 2003, 3:665-673.
23. Worthington J.E., McEwen A., McWilliam L.J., Picton M.L., Martin S Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome. Transplantation 2007, 83:398-403.
24. Farris A.B., Gaut J., Wong W., Della Pelle P., Brousaides N., Collins A.B., et al. Pathology, serology and clinical characteristics of 68 patients with chronic humoral renal allograft rejection (CHR). Laboratory Investigation 2009, 89:302A-303A.
25. Kieran N., Wang X., Perkins J., Davis C., Kendrick E., Bakthavatsalam R., et al. Combination of peritubular c4d and transplant glomerulopathy predicts late renal allograft failure. J Am Soc Nephrol 2009, 20:2260-2268.
26. Gloor J.M., Sethi S., Stegall M.D., Park W.D., Moore S.B., DeGoey S., et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007, 7:2124-2132.
27. Solez K., Colvin R.B., Racusen L.C., Sis B., Halloran P.F., Birk P.E., et al. Banff'05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). Am J Transplant 2007, 7:518-526.
28. Aita K., Yamaguchi Y., Shimizu T., Horita S., Furusawa M., Tanabe K., et al. Histological analysis of late renal allografts of antidonor antibody positive patients with C4d deposits in peritubular capillaries. Clin Transpl 2004, 11(18 Suppl.):7-12.
29. Cosio F.G., Gloor J.M., Sethi S., Stegall M.D., Transplant glomerulopathy Am J Transplant 2008, 8:492-496.
30. Hidalgo L.G., Campbell P.M., Sis B., Einecke G., Mengel M., Chang J., et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009, 9:2532-2541.
31. Einecke G., Sis B., Reeve J., Mengel M., Campbell P.M., Hidalgo L.G., et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009, 9:2520-2531.
32. Ishii Y., Sawada T., Kubota K., Fuchinoue S., Teraoka S., Shimizu A. Injury and progressive loss of peritubular capillaries in the development of chronic allograft nephropathy. Kidney Int 2005, 67:321-332.
33. Tinckam K.J., Djurdjev O., Magil A.B. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int 2005, 68:1866-1874.
34. Ashton-Chess J., Dugast E., Colvin R.B., Giral M., Foucher Y., Moreau A., et al. Regulatory, effector, and cytotoxic T cell profiles in long-term kidney transplant patients. J Am Soc Nephrol 2009, 20:1113-1122.
35. Yamamoto I., Horita S., Takahashi T., Tanabe K., Fuchinoue S., Teraoka S., et al. Glomerular expression of plasmalemmal vesicle-associated protein-1 in patients with transplant glomerulopathy. Am J Transplant 2007, 7:1954-1960.
36. Collins A.B., Farris A.B., Smith R.N., Adams C.D., Della Pelle P.A., Saidman S., et al. Challenges in the diagnosis of chronic antibody mediated rejection due to loss of peritubular capillaries and low extent and transient nature of C4d deposition. Laboratory Investigation 2009, 89:301A-302A.
37. Smith R.N., Kawai T., Boskovic S., Nadazdin O., Sachs D.H., Cosimi A.B., et al. Chronic antibody mediated rejection of renal allografts: pathological, serological and immunologic features in nonhuman primates. Am J Transplant 2006, 6:1790-1798.
38. Smith R.N., Kawai T., Boskovic S., Nadazdin O., Sachs D.H., Cosimi A.B., et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant 2008, 8:1662-1672.
39. Mengel M., Bogers J., Bosmans J.L., Seron D., Moreso F., Carrera M., et al. Incidence of C4d stain in protocol biopsies from renal allografts: results from a multicenter trial. Am J Transplant 2005, 5:1050-1056.
40. Haas M., Montgomery R.A., Segev D.L., Rahman M.H., Racusen L.C., Bagnasco S.M., et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007, 7:576-585.
41. Bach F.H., Ferran C., Candinas D., Miyatake T., Koyamada N., Mark W., et al. Accommodation of xenografts: expression of " protective genes" in endothelial and smooth muscle cells. Transplant Proc 1997, 29:56-58.
42. Rother R.P., Arp J., Jiang J., Ge W., Faas S.J., Liu W., et al. C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients. Am J Transplant 2008, 8:1129-1142.
43. Ding J.W., Zhou T., Ma L., Yin D., Shen J., Ding C.P., et al. Expression of complement regulatory proteins in accommodated xenografts induced by anti-alpha-Gal IgG1 in a rat-to-mouse model. Am J Transplant 2008, 8:32-40.
44. Salama A.D., Delikouras A., Pusey C.D., Cook H.T., Bhangal G., Lechler R.I., et al. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001, 1:260-269.
45. Gonzalez-Stawinski G.V., Tan C.D., Smedira N.G., Starling R.C., Rodriguez E.R. Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection. J Heart Lung Transplant 2008, 27:357-361.
46. Park W.D., Grande J.P., Ninova D., Nath K.A., Platt J.L., Gloor J.M., et al. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003, 3:952-960.
47. Fan X., Ang A., Pollock-Barziv S.M., Dipchand A.I., Ruiz P., Wilson G., et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med 2004, 10:1227-1233.
48. Wang H., Arp J., Liu W., Faas S.J., Jiang J., Gies D.R., et al. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol 2007, 179:4451-4463.
49. Terasaki P.I., Ci J. Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005, 17:541-545.
50. Zou Y., Stastny P., Susal C., Dohler B., Opelz G. Antibodies against M.I.C.A. antigens kidney-transplant rejection. N Engl J Med 2007, 357:1293-1300.
51. Li L., Chen A., Chaudhuri A., Kambham N., Sigdel T., Chen R., et al. Compartmental localization and clinical relevance of MICA antibodies after renal transplantation. Transplantation 2010, 89:312-319.
52. Porcheray F., DeVito J., Yeap B.Y., Xue L., Dargon I., Paine R., et al. Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses. Transplantation 2010, 89:1239-1246.
53. Jackson A.M., Lucas D.P., Melancon J.K., Desai N.M. Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation 2011, 92:54-60.
54. Reinsmoen N.L., Lai C.H., Heidecke H., Haas M., Cao K., Ong G., et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010, 90:1473-1477.
55. Yabu J.M., Higgins J.P., Chen G., Sequeira F., Busque S., Tyan D.B. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011, 91:342-347.
56. Honger G., Wahrmann M., Amico P., Hopfer H., Bohmig G.A., Schaub S. C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 2010, 89:1471-1475.
57. Honger G., Hopfer H., Arnold M.L., Spriewald B.M., Schaub S., Amico P. Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation 2011, 92:41-47.
58. Gao Z.H., McAlister V.C., Wright J.R., McAlister C.C., Peltekian K., MacDonald AS Immunoglobulin-G subclass antidonor reactivity in transplant recipients. Liver Transpl 2004, 10:1055-1059.
59. Heinemann F.M., Roth I., Rebmann V., Arnold M.L., Witzke O., Wilde B., et al. Immunoglobulin isotype-specific characterization of anti-human leukocyte antigen antibodies eluted from explanted renal allografts. Hum Immunol 2007, 68:500-506.
60. Murata K., Fox-Talbot K., Qian Z., Takahashi K., Stahl G.L., Baldwin W.M., et al. Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants. Am J Transplant 2007, 7:2605-2614.
61. Singh N., Djamali A., Lorentzen D., Pirsch J.D., Leverson G., Neidlinger N., et al. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 2010, 90:1079-1084.
62. Susal C., Ovens J., Mahmoud K., Dohler B., Scherer S., Ruhenstroth A., et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation 2011, 91:883-887.
63. Takahashi K., Saito K., Nakagawa Y., Tasaki M., Hara N., Imai N Mechanism of acute antibody-mediated rejection in ABO-incompatible kidney transplantation: which anti-A/anti-B antibodies are responsible, natural or de novo?. Transplantation 2010, 89:635-637.
64. Russell P.S., Chase C.M., Winn H.J., Colvin RB Coronary atherosclerosis in transplanted mouse hearts II. Importance of humoral immunity. J Immunol 1994, 152:5135-5141.
65. Russell P.S., Chase C.M., Colvin R.B. Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation 1997, 64:1531-1536.
66. Uehara S., Chase C.M., Cornell L.D., Madsen J.C., Russell P.S., Colvin RB Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody C4d deposition and neointimal fibrosis. Am J Transplant 2007, 7:57-65.
67. Qian Z., Hu W., Liu J., Sanfilippo F., Hruban R.H., Baldwin W.M. Accelerated graft arteriosclerosis in cardiac transplants: complement activation promotes progression of lesions from medium to large arteries. Transplantation 2001, 72:900-906.
68. Hirohashi T., Uehara S., Chase C.M., DellaPelle P., Madsen J.C., Russell P.S., et al. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant 2010, 10:510-517.
69. Jin Y.P., Jindra P.T., Gong K.W., Lepin E.J., Reed EF Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation 2005, 79:S19-S21.
70. Hirohashi T., Uehara S., Chase C.M., Madsen J.C., Russell P.S., Colvin RB Antibody mediated, complement independent transplant arteriopathy in mice. Am J Transplant 2008, 8:179-180.
71. Jindra P.T., Jin Y.P., Rozengurt E., Reed E.F. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 2008, 180:2357-2366.
72. Nimmerjahn F., Ravetch J.V. Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 2008, 8:34-47.
73. Colvin R.B. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007, 18:1046-1056.
74. Stegall M.D., Cornell L., S R., Gloor J. Terminal complement blockade in sensitized renal transplant recipients. American Transplant Congress 2011 2011, Abstract # 197.
75. Shimizu I., Smith N.R., Zhao G., Medof E., Sykes M. Decay-accelerating factor prevents acute humoral rejection induced by low levels of anti-alphaGal natural antibodies. Transplantation 2006, 81:95-100.
76. Colvin RB Pathology of chronic humoral rejection. Contrib Nephrol 2009, 162:75-86.
77. Sis B., Jhangri G.S., Bunnag S., Allanach K., Kaplan B., Halloran P.F. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009.
78. Yin D., Zeng H., Ma L., Shen J., Xu H., Byrne G.W., et al. Cutting edge: NK cells mediate IgG1-dependent hyperacute rejection of xenografts. J Immunol 2004, 172:7235-7238.
79. Hirohashi T., Chase C.M., Della Pelle P., Sebastian D., Alessandrini A., Madsen J.C., et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2011, 20.
80. Hidalgo L.G., Sis B., Sellares J., Campbell P.M., Mengel M., Einecke G., et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010, 10:1812-1822.
81. Carroll MC The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol 1998, 16:545-568.
82. Brandle D., Joergensen J., Zenke G., Burki K., Hof RP Contribution of donor-specific antibodies to acute allograft rejection: evidence from B cell-deficient mice. Transplantation 1998, 65:1489-1493.
83. Wasowska B.A., Qian Z., Cangello D.L., Behrens E., Van Tran K., Layton J., et al. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplantation 2001, 71:727-736.
84. Liu C., Noorchashm H., Sutter J.A., Naji M., Prak E.L., Boyer J., et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med 2007, 13:1295-1298.
85. Wasowska B.A., Lee C.Y., Halushka M.K., Baldwin W.M. New concepts of complement in allorecognition and graft rejection. Cell Immunol 2007, 248:18-30.
86. Richards S., Watanabe C., Santos L., Craxton A., Clark EA Regulation of B-cell entry into the cell cycle. Immunol Rev 2008, 224:183-200.
87. Okada T., Cyster JG B cell migration and interactions in the early phase of antibody responses. Curr Opin Immunol 2006, 18:278-285.
88. Crotty S Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011, 29:621-663.
89. Honjo T., Muramatsu M., Fagarasan S AID: how does it aid antibody diversity?. Immunity 2004, 20:659-668.
90. Allen C.D., Okada T., Cyster JG Germinal-center organization and cellular dynamics. Immunity 2007, 27:190-202.
91. McHeyzer-Williams L.J., McHeyzer-Williams M.G. Antigen-specific memory B cell development. Annu Rev Immunol 2005, 23:487-513.
92. Zarkhin V., Kambham N., Li L., Kwok S., Hsieh S.C., Salvatierra O., et al. Characterization of intra-graft B cells during renal allograft rejection. Kidney Int 2008, 74:664-673.
93. Sarwal M., Chua M.S., Kambham N., Hsieh S.C., Satterwhite T., Masek M., et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003, 349:125-138.
94. Scheepstra C., Bemelman F.J., van der Loos C., Rowshani A.T., van Donselaar-Van der Pant K.A., Idu M.M., et al. B cells in cluster or in a scattered pattern do not correlate with clinical outcome of renal allograft rejection. Transplantation 2008, 86:772-778.
95. Kerjaschki D., Regele H.M., Moosberger I., Nagy-Bojarski K., Watschinger B., Soleiman A., et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol 2004, 15:603-612.
96. Smith R.N., Chang Y., Houser S., Dec G.W., Grazette L Higher frequency of high-grade rejections in cardiac allograft patients after Quilty B lesions or grade 2/4 rejections. Transplantation 2002, 73:1928-1932.
97. Poduval R.D., Kadambi P.V., Josephson M.A., Cohn R.A., Harland R.C., Javaid B., et al. Implications of immunohistochemical detection of C4d along peritubular capillaries in late acute renal allograft rejection. Transplantation 2005, 79:228-235.
98. Einecke G., Reeve J., Mengel M., Sis B., Bunnag S., Mueller T.F., et al. Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts. Am J Transplant 2008, 8:1434-1443.
99. Thaunat O., Patey N., Gautreau C., Lechaton S., Fremeaux-Bacchi V., Dieu-Nosjean M.C., et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation 2008, 85:1648-1653.
100. Li L., Wadia P., Chen R., Kambham N., Naesens M., Sigdel T.K., et al. Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and " antibodyome" measures. Proc Natl Acad Sci USA 2009, 106:4148-4153.
101. Dragun D., Muller D.N., Brasen J.H., Fritsche L., Nieminen-Kelha M., Dechend R., et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352:558-569.
102. MacLennan I.C., Toellner K.M., Cunningham A.F., Serre K., Sze D.M., Zuniga E., et al. Extrafollicular antibody responses. Immunol Rev 2003, 194:8-18.
103. McHeyzer-Williams M.G., Ahmed R. B cell memory and the long-lived plasma cell. Curr Opin Immunol 1999, 11:172-179.
104. Meehan SM Differences in AR episodes, plasma cell content, immunohistology, for C4d, chronic allograft nephropathy scores, and graft survival in patients with predominantly CMV infection. Mod Pathol 2004, 17:1302. author reply: 1303.
105. Desvaux D., Le Gouvello S., Pastural M., Abtahi M., Suberbielle C., Boeri N., et al. Acute renal allograft rejections with major interstitial oedema and plasma cell-rich infiltrates: high gamma-interferon expression and poor clinical outcome. Nephrol Dial Transplant 2004, 19:933-939.
106. Thaunat O., Field A.C., Dai J., Louedec L., Patey N., Bloch M.F., et al. Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc Natl Acad Sci USA 2005, 102:14723-14728.
107. Faguer S., Kamar N., Guilbeaud-Frugier C., Fort M., Modesto A., Mari A., et al. Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation 2007, 83:1277-1280.
108. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
109. Ruggenenti P., Chiurchiu C., Abbate M., Perna A., Cravedi P., Bontempelli M., et al. Rituximab for idiopathic membranous nephropathy: who can benefit?. Clin J Am Soc Nephrol 2006, 1:738-748.
110. Bokarewa M., Lindholm C., Zendjanchi K., Nadali M., Tarkowski A Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol 2007, 66:476-483.
111. Cree B Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 2006, 12:171-178.
112. Hu C.Y., Rodriguez-Pinto D., Du W., Ahuja A., Henegariu O., Wong F.S., et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007, 117:3857-3867.
113. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
114. Pescovitz MD Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006, 6:859-866.
115. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
116. Shapiro R., Basu A., Zeevi A., Lunz J., Mapara M., Randhawa P., et al. Bortezomib rescue in refractory acute humoral rejection - report of a case. Clin Transpl 2009, 431-432.
117. Pavlakis M Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC. Clin Transpl 2009, 343-345.
118. Mai H.L., Cesbron A., Brouard S., Blanchol G., Cantarovich D., Dantal J., et al. Bortezomib in the treatment of antibody-mediated rejection - a report of 3 cases. Clin Transpl 2009, 361-368.
119. Lachmann N., Schutz M., Budde K., Schonemann C., Waiser J. Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series. Clin Transpl 2009, 351-358.
120. Island E.R., Gonzalez-Pinto I.M., Tsai H.L., Ruiz P., Tryphonopoulos P., Gonzalez M.L., et al. Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation. Clin Transpl 2009, 465-469.
121. Sberro-Soussan R., Zuber J., Suberbielle-Boissel C., Legendre C Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports. Clin Transpl 2009, 433-438.
122. Lateef A., Petri M Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 2010, 22:504-509.
123. Ramanujam M., Davidson A BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled?. Immunol Rev 2008, 223:156-174.
124. Boskovic S., Smith R.N., Kawai T., Nadazdin O., Sachs D.H., Cosimi A.B., et al. Inhibitory effects of Atacicept (TACI-IG) on circulating antibodies, B cells and plasma cells in allosensitized cynomolgus monkeys. XXII International Transplant Congress 2008, Abstract # 463.
125. Zhou P., Comenzo R.L., Olshen A.B., Bonvini E., Koenig S., Maslak P.G., et al. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood 2008, 111:3403-3406.